Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander G G Turpie

Showing results (61-70 of 177) with videos related to

Pageof 18
Sort By:
The Annals of Pharmacotherapy|May 15, 2008
Drug reimbursement policies in Canada--need for improved access to critical therapiesJacques LeLorier, Alan Bell, David J Bougher, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2015
Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical PracticeMichael R Lassen, Sylvia Haas, Reinhold Kreutz, et al.
Thrombosis Research|February 7, 2018
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable stateCraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
The American Journal of Medicine|December 25, 2018
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTECraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Circulation|October 17, 2012
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literatureFrancesco Dentali, Nicoletta Riva, Mark Crowther, et al.
Vascular Medicine (London, England)|July 10, 2007
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?Alexander T Cohen, Alexander G G Turpie, Alain Leizorovicz, et al.
Thrombosis and Haemostasis|January 5, 2005
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patientsPaul T Vaitkus, Alain Leizorovicz, Alexander T Cohen, et al.
Circulation|August 4, 2004
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsAlain Leizorovicz, Alexander T Cohen, Alexander G G Turpie, et al.
Vascular Health and Risk Management|August 2, 2014
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillationA John Camm, Pierre Amarenco, Sylvia Haas, et al.
British Journal of Clinical Pharmacology|November 19, 2015
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactionsReinhold Kreutz, Sylvia Haas, Gerlind Holberg, et al.
Pageof 18

Showing results (61-70 of 177) with videos related to

Sort By:
Pageof 18
The Annals of Pharmacotherapy|May 15, 2008
Drug reimbursement policies in Canada--need for improved access to critical therapiesJacques LeLorier, Alan Bell, David J Bougher, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2015
Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical PracticeMichael R Lassen, Sylvia Haas, Reinhold Kreutz, et al.
Thrombosis Research|February 7, 2018
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable stateCraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
The American Journal of Medicine|December 25, 2018
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTECraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Circulation|October 17, 2012
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literatureFrancesco Dentali, Nicoletta Riva, Mark Crowther, et al.
Vascular Medicine (London, England)|July 10, 2007
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?Alexander T Cohen, Alexander G G Turpie, Alain Leizorovicz, et al.
Thrombosis and Haemostasis|January 5, 2005
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patientsPaul T Vaitkus, Alain Leizorovicz, Alexander T Cohen, et al.
Circulation|August 4, 2004
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsAlain Leizorovicz, Alexander T Cohen, Alexander G G Turpie, et al.
Vascular Health and Risk Management|August 2, 2014
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillationA John Camm, Pierre Amarenco, Sylvia Haas, et al.
British Journal of Clinical Pharmacology|November 19, 2015
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactionsReinhold Kreutz, Sylvia Haas, Gerlind Holberg, et al.
Pageof 18